Dopamine cell therapy for Parkinson’s shows promise

Just one shot of dopamine cells derived from stem cells could be enough to reverse many of the features of Parkinson’s disease for decades – and the barriers to developing such a treatment are finally being overcome.

Professor Roger Barker has a dream: by the time he retires in 15 years, he would like to see for Parkinson’s disease available on the NHS.

Continue reading

Researchers work to find treatments for Parkinson’s

Not long after actor and comedian Robin Williams’ Aug. 11 suicide, fans learned that the 63-year-old Oscar winner had recently been diagnosed with Parkinson’s disease.  In the days following Williams’ death, his widow, Susan Schneider, revealed the news and maintained the actor — who had struggled with substance abuse since the 1980s and checked into rehab this summer to maintain sobriety — was sober at the time of his death.  “Robin’s sobriety was intact and he was brave as he struggled with his own battles of depression, anxiety as well as early stages of Parkinson’s disease, which he was not yet ready to share publicly,” she said in a statement.  While Parkinson’s disease is common, said Jerry Henberger, executive director of the Parkinson’s Association of San Diego, it’s also misunderstood.

Continue reading

Parkinson’s therapy aims to help retrain brains

BRIDGEWATER, Pa. (AP) — Parkinson’s robs people of the ability to control their movements, but some patients in Beaver County are seeing big results from a physical therapy program designed to counteract the symptoms of the degenerative disease.

While there is no cure for Parkinson’s disease and little is known about the cause, experts know that people with the nervous system disorder have trouble with slowness of movement, and their movements are also small, said Dale Reckless, facility director of M-R-S Physical Therapy in Bridgewater.

But the Lee Silverman Voice Treatment Big (LSVT Big) therapy program, which Reckless brought to M-R-S and Beaver County earlier this year, is aimed at keeping people’s movements big and quick in order to counteract those symptoms.

Continue reading

Research targets early symptoms of Parkinson’s

University of Adelaide neuroscience researchers are investigating markers for potential earlier diagnosis and treatment of Parkinson’s disease.  The researchers are studying the molecular basis of non- of Parkinson’s disease, rather than the better-known clinical symptoms of impaired movement. These “non-motor” symptoms include , depression and anxiety – and they can appear several years before the emergence of motor symptoms.

 

Continue reading

Dutch MedTech Startup Team Brings Fresh Hope For Sufferers Of Parkinson’s Disease

Timing is everything in business; especially where groundbreaking medical treatments, investments and acquisitions are concerned.  So when a pioneering med-tech start-up comes up with a new treatment for Parkinson’s disease – effectively a next generation pacemaker for the brain – the business and investment world takes notice.

Continue reading

World Parkinson Coalition to Hold Online Conference

The World Parkinson Coalition (WPC) is hosting its first ever WPC Scientific Update online for free September 30 to October 1.

WPC Scientific Update: Parkinson Pipeline Umbrella will take place over three days in six one-hour sessions at 12 p.m. ET/9 a.m. PT and at 2 p.m. ET/ 11 p.m. PT. In addition to the live webcast, the sessions will archived for later viewing.

Sessions will be about the latest scientific updates from the Parkinson’s research world. Thefull program is available online. Participants are also encouraged to tweet before and during the sessions using the hashtag #WPCwebcast.

For more information and to register, click here.

NeuroDerm Starts Phase 2a Study of Parkinson’s Drug

NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, announced that the first patients with severe Parkinson’s disease have been enrolled and dosed in a Phase 2a trial of ND0612H. ND0612H is a high-dose form of NeuroDerm’s proprietary liquid levodopa/carbidopa (LD/CD) drug formulation, delivered continuously through subcutaneous administration by a belt-pump.

Entia Biosciences Awarded Grant from Michael J. Fox Foundation

Entia Biosciences Inc. (OTC: ERGO), an emerging leader in the field of nutrigenomics, was recently awarded a grant from the Michael J. Fox Foundation to conduct a preclinical study evaluating its ErgoD2® medical food as a potential therapy for the treatment of Parkinson’s Disease. Approximately 60,000 Americans are diagnosed with PD each year, with an estimated one million living with the disease.

To syndicate this article, or for more information, please contact us online or call (406) 862-5400.

Continue reading

Link Between Parkinson’s Disease And Creativity

Tel Aviv University

New TAU study confirms creative energy in Parkinson’s sufferers is greater than in healthy individuals

Prof. Rivka Inzelberg of Tel Aviv University’s Sackler Faculty of Medicine and the Sagol Neuroscience Center at Sheba Medical Center, Tel Hashomer, documented the exceptional creativity of Parkinson’s patients two years ago in a review for Behavioral Neuroscience. Since then, she has conducted the first empirical study to verify a link between Parkinson’s disease and artistic inclination.

Continue reading

Cynapsus Therapeutics Commences Phase 2 Clinical Trials in the United States

TORONTO, ONTARIO–(Marketwired – July 17, 2014) – Cynapsus Therapeutics Inc. (TSX VENTURE:CTH)(OTCQX:CYNAF), a specialty pharmaceutical company focused on Parkinson’s disease, today announced that following communication from the United States Food and Drug Administration (“the FDA”) on July 16, 2014, Phase 2 clinical studies for APL-130277 will commence immediately.